Phaseline

Companies › Psoriasis Research Institute of Guangzhou

Psoriasis Research Institute of Guangzhou: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 3; Immunology; next expected readout Dec 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Total Coumarin (TC) Cream
Botanical coumarin mixture for topical treatment of psoriasis
–Phase 3Psoriasis VulgarisDec 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07426120Total Coumarin (TC) CreamPhase 3Psoriasis VulgarisImmunologyDec 2027

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Biopharma Plasma KalVista Pharmaceuticals Triple Hair Infant Bacterial Therapeutics Aresus Pharma

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.